Reduction in both liver fat and ALT have been demonstrated with Empagliflozin among T2DM patients with NAFLD, irrespective of glycemic improvement and body weight reduction.30 Takase et al found from sub-analysis of 16-weeks, prospective observational study that Ipragliflozin was associated with amelioration of hepatic steatosis by decrease in Fibrosis Index-4 (FIB-4), a surrogate measure for fatty liver31, in addition to a reduction in ALT level. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.